Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.80 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL1170449 | 1.00 | CA5A (0.80) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL10871447 | 1.00 | — | — | |
| Nitric Acid SCHEMBL16265935 | 1.00 | — | — | |
| Nitric Acid SCHEMBL28159131 | 0.95 | CA5A (0.73) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL479716 | 0.95 | — | — | |
| Nitric Acid SCHEMBL228897 | 0.95 | CA5A (0.89) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL8510743 | 0.95 | CA5A (0.89) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL1943526 | 0.95 | — | — | |
| Nitric Acid SCHEMBL21523563 | 0.95 | CA5A (0.89) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL19616567 | 0.95 | CA5A (0.89) | CA5ACA5BMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117776718-A | Preparation method of target particles for metal oxide irradiation | 中核四0四有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-119263356-A | Spherical (LPSGY) FO high-entropy nano material and preparation method and application thereof | 渤海大学 | 2025-01-07 | — | — | CN | disclosed |
| WO-2024254831-A1 | RARE EARTH IODATE MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院福建物质结构研究所 | 2024-12-19 | — | — | WO | disclosed |
| CN-118403162-A | X-ray activated free radical generation nano material and application thereof | 北京医院 | 2024-07-30 | — | — | CN | disclosed |
| CN-117776718-A | Preparation method of target particles for metal oxide irradiation | 中核四0四有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-116924453-A | Rare earth iodate material and preparation method and application thereof | 中国科学院福建物质结构研究所 | 2023-10-24 | — | — | CN | disclosed |
| CN-109385897-B | Preparation method of composite yarn containing metal organic framework nanofiber | 扬州云彩新材料科技有限公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-102077396-A | Positive electrode active material for non-aqueous electrolyte secondary battery, method for production of positive electrode active material for non-aqueous electrolyte secondary battery, positive electrode for non-aqueous electrolyte secondary batt | SANYO ELECTRIC CO | 2011-05-25 | — | — | CN | disclosed |
| US-20060292072-A1 | Agents for neutron capture therapy | PHARMACYCLICS, INC. (US) | 2006-12-28 | — | — | US | disclosed |
| EP-1362861-B1 | Macrocyclic chelants for metallopharmaceuticals | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040023891-A1 | Agents for neutron capture therapy | PHARMACYCLICS, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6685914-B1 | CONTRAST AGENTS IN X-RAY IMAGING, MAGNETIC RESONANCE IMAGING (MRI) AND RADIOPHARMACEUTICALS, HEAVY METAL DETOXIFICATION; 1,4,8,11-TETRAAZA-6,13-PHOSPHACYCLOTETRADECANE COMPOUND WITH PHOSPHINIC BRIDGES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-03 | — | — | US | disclosed |
| EP-1362861-A1 | Macrocyclic chelants for metallopharmaceuticals | Bristol-Myers Squibb Pharma Company (US) | 2003-11-19 | — | — | EP | disclosed |
| EP-1246830-B1 | MACROCYCLIC CHELANTS FOR METALLOPHARMACEUTICALS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1246830-A1 | MACROCYCLIC CHELANTS FOR METALLOPHARMACEUTICALS | Bristol-Myers Squibb Pharma Company (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2002017910-A1 | AGENTS FOR NEUTRON CAPTURE THERAPY | PHARMACYCLICS, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001019838-A1 | MACROCYCLIC CHELANTS FOR METALLOPHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-03-22 | — | — | WO | disclosed |
| US-5892029-A | HIGHLY EFFECTIVE UPON BOTH INJECTION AND ORAL ADMINISTRATION. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-04-06 | — | — | US | disclosed |
| EP-0840727-A1 | 3-HYDROXY-2(1H)-PYRIDINONE CHELATING AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-05-13 | — | — | EP | disclosed |
| WO-1997000245-A1 | 3-HYDROXY-2(1H)-PYRIDINONE CHELATING AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023891-A1 | Agents for neutron capture therapy | NME1, NUCB2, NME2 | CA5A 757/4885CA5B 279/4885MEN1 269/4885 |
| US-20060292072-A1 | Agents for neutron capture therapy | NME1, NUCB2, NME2 | CA5A 757/4885CA5B 279/4885MEN1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.